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THE DIFFERENCES BETWEEN ORAL VITAMIN C AND IV VITAMIN C IN 
CORONARY HEART DISEASE : A REVIEW LITERATURE 
B,A. Mahdi 1*, Y.Purnamasari,2*, JK Fajar3* 
1 MD at Aisyiyah Islamic Hospital Malang, East Java, Indonesia 
2 Internship Doctor at Aisyiyah Islamic Hospital Malang, East Java, Indonesia 
3 MD at Hasanah Islamic Hospital Mojokerto, East Java, Indonesia 
Background: Some studies have shown that low level of vitamin C has a role on developing 
coronary heart disease. Chronic insufficiency of vitamin C lead the damage of blood vessel. This 
damage triggers some biological repair process in which cholesterol-carrying lipoproteins deposit 
in the arterial wall, lead up atherosclerosis, changes the cells of the artery wall and blood 
components.The change makes increasing oxidative stress substances, Reactive Oxygen Species 
(ROS), and Nitric Oxide (NO) making endothelial dysfunction, plug rupture and becoming acute 
myocardial infarct. 
Objective: This study aims to review the different benefit effect of oral vitamin C and IV vitamin 
C in coronary heart disease. 
Material and methods: Authors were using literature review. Published papers from 20 studied 
were identified for the review based on like PubMed, Cochrane, Google Scholar, Medline. 
Keyword were “vitamin C” and “coronary” and “cardiovascular”. This method will bring a new 
knowledge about vitamin C treatment in coronary heart disease. 
Result(s):High plasma level vitamin C limiting generation of ROS, and repairing other oxidized 
scavengers and modulating numerous enzyme reactions, but can also act as a direct radical 
scavengers. In addition, vitamin C maintain NO mediated endothelial integrity and vasomotor 
control of coronary vessels. From 5 studies, oral vitamin C shown that no effect for improving 
outcome coronary heart disease and 2 studies intravenous vitamin C have shown improving 
myocardial injury on coronary heart disease who undergoing elective PCI. 
Conclusion: Intravenous Vitamin C has better result than oral Vitamin C for coronary heart 
disease. It is reducing micro reperfusion injury on coronary heart disease patient who undergoing 
elective PCI.  
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WHICH ANTITHROMBOTIC(S) SHOULD BE GIVEN TO PATIENT UNDERGOING 
TRANSCATHETER AORTIC VALVE REPLACEMENT? -  A SYSTEMATIC REVIEW 
AND META-ANALYSIS 
Raymond Pranata1, Emir Yonas2, Bambang Pamungkas3, Bambang Budi Siswanto4, Budhi 
Setianto Purwowiyoto4 
1Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia 
2Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia 
3Department of Cardiology and Vascular Medicine, Central Army Hospital Gatot Soebroto, 
Jakarta, Indonesia 
4Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, 
National Cardiovascular Center Harapan Kita, Jakarta, Indonesia 
 
Introduction 
Dual antiplatelet therapy (DAPT) has been used widely in patients undergoing transcatheter aortic 
valve replacement (TAVR) with uncertain clinical evidence. The aim of this study is to compare 
the efficacy and safety of DAPT, single antiplatelet therapy (SAPT) with or without oral 
anticoagulant (OAC). 
Methods 
Electronic search on PubMed (MEDLINE), EBSCO, EuropePMC, Cochrane Central Database, 
Clinicaltrials.gov, and Google Scholar was done. Studies comparing the use of DAPT or SAPT 
with/without OAC in patients undergoing TAVR was included. Meta-analysis directly compared 
the outcome of DAPT vs SAPT + OAC, DAPT vs SAPT, and indirectly compared SAPT vs SAPT 
+ OAC. There were 13 studies included. 
 
Results 
A total of 4 studies (931 patients) that compared DAPT and SAPT + OAC were included. There 
was no significant difference in mortality, stroke/TIA, and bleeding rate between these groups. An 
analysis of 5-7 studies (752-1301 patients) comparing DAPT and SAPT yield a non-significant 
outcome in terms of 30-days all-cause mortality, all-cause mortality, stroke/TIA, and myocardial 
infarction. However, life-threatening/major bleeding was significantly higher in those who took 
DAPT [RR = 1.98, 95% CI 1.13-3.45, p=0.02 albeit high heterogeneity] number needed to harm 
for major/life-threatening bleeding was 12.5. On indirect analysis comparing SAPT vs SAPT + 
OAC, there was no significant difference in mortality, stroke/TIA, and major bleeding. 
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Mortality, stroke/TIA, and myocardial infarction were statistically not significant between groups. 
However, the number of major/life-threatening bleeding was highest in DAPT. Since DAPT or 
OAC did not have better efficacy and SAPT having an edge in safety, the latter may suffice in 
patients undergoing TAVR. 
Figure 1. Meta-analysis of all-cause mortality. Comparator: DAPT vs SAPT + OAC 
 
Figure 2. Meta-analysis of Major Bleeding. Comparator: DAPT vs SAPT + OAC 
 
Figure 3. Meta-analysis of all-cause mortality. Comparator: DAPT vs SAPT 
 
Figure 4. Meta-analysis of Stroke/TIA. Comparator: DAPT vs SAPT 
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PERCUTANEOUS CORONARY INTERVENTION VS CORONARY ARTERY BYPASS 
GRAFTING IN UNPROTECTED LEFT MAIN ARTERY DISEASE - SYSTEMATIC 
REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL 
Raymond Pranata1, Emir Yonas2, Bambang Pamungkas3, Vito Damay1,4 
1Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia 
2Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia 
3Department of Cardiology and Vascular Medicine, Central Army Hospital Gatot Soebroto, 
Jakarta, Indonesia 
4Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, Tangerang, 
Indonesia 
Introduction 
Percutaneous coronary intervention (PCI) emerges as a less invasive alternative to the routinely 
done coronary artery bypass grafting (CABG) for management of unprotected left main coronary 
artery (ULMCA) disease. This meta-analysis aimed to compare the efficacy of PCI and CABG in 
the management of ULMCA disease. 
Methods 
Electronic search on PubMed (MEDLINE), EBSCO, EuropePMC, Cochrane Central Database, 
Clinicaltrials.gov, and Google Scholar was done. Randomized controlled trials comparing the use 
of PCI or CABG in patients with ULMCA stenosis were included. Meta-analysis was done to 
compare the outcome of PCI and CABG. There were 6 studies included. 5 studies exclusively used 
Drug-Eluting Stent (DES) and 1 study used both Bare Metal Stent (BMS) and DES. The primary 
outcome of interest was all-cause mortality and secondary was CV death, MACE, myocardial 
infarction (MI), stroke, and repeat revascularization. 
 
Results 
There were a total of 4688 participants from 6 studies. PCI of ULMCA was associated with similar 
all-cause mortality, CV death, 1-year MACE, MI, and stroke. However, PCI had a higher rate of 
repeat revascularization [OR 1.78; 95% CI 1.48-2.15; p<0.001] and 3-5-year MACE [OR 1.40; 
95% CI 1.21-1.62; p<0.001]. After ousting 1 study that used a mixture of BMS and DES, the result 
is still significant for repeat revascularization [OR 1.85; 95% CI 1.53-2.23; p<0.001] and 3-5-year 
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Coronary artery bypass graft still upholds the advantage over PCI in ULMCA revascularization. 
However, PCI is non-inferior in terms of all-cause mortality, CV death, 1-year MACE, MI, and 
stroke. Percutaneous coronary intervention can be considered as an acceptable option in inoperable 
patients. 
Figure 1. Meta-analysis of 3-5 years Major Adverse Cardiovascular Events. Comparator: PCI vs 
CABG 
 
Figure 2. Meta-analysis of Repeat Revascularization. Comparator: PCI vs CABG 
 




Indonesian Journal of 
Cardiology 
Indonesian J Cardiol 
2018:39:suppl_B:133-149 
pISSN: 0126-3773 / eISSN: 2620-4762 
doi: 10.30701/ijc.v39iSuppl_B.856 
 
Abstracts of the 10th Indonesian Society of Interventional Cardiology Annual Meeting 2018 
139 
 
IS FOLATE BENEFICIAL OR HARMFUL IN POST-PERCUTANEOUS CORONARY 
INTERVENTION PATIENTS? -  A SYSTEMATIC REVIEW AND META-ANALYSIS 
OF RANDOMIZED CONTROLLED TRIALS 
Raymond Pranata1, Emir Yonas2, Rachel Vania3, Bambang Budi Siswanto4, Budhi Setianto 
Purwowiyoto4 
1Assistant Physician, Siloam Hospitals Lippo Village – Faculty of Medicine Universitas Pelita 
Harapan, Tangerang, Indonesia 
2Faculty of Medicine Universitas YARSI, Jakarta, Indonesia 
3Intern, Gatot Soebroto Army Central Hospital, Jakarta, Indonesia 
4Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, 
National Cardiovascular Center Harapan Kita, Jakarta, Indonesia 
Introduction 
Elevated homocysteine level was found to be an independent predictor of cardiovascular and all-
cause mortality. Folic acid was shown to be able to reduce the homocysteine level. However, folic 
acid/folate was found to induce restenosis in post-percutaneous coronary intervention (PCI) 
patients according to one double-blind randomized controlled trial (RCT). Our aim is to investigate 
whether folate is harmful in post-PCI patients. 
Methods 
Search on [(folate) OR (folic acid) AND (restenosis)] and its synonyms were conducted through 
PubMed, EuropePMC, EBSCOhost and snowballing. The primary outcome was restenosis. Two 
authors independently extracted and assessed the risk of bias. Only double-blind RCT in the 
English language were included. A total of 242 results were found, 4 were relevant titles/abstract. 




There were a total of 1594 post-PCI patients from 4 double-blind RCT.3-6 Three studies that 
measured homocysteine levels demonstrated a significant reduction in homocysteine levels at 
follow-up. The results on minimal lumen diameter (MLD) was conflicting in two studies. Folate 
regimen caused restenosis in a study involving 636 patients but other studies showed either 
reduction or no effect on restenosis. One of the studies that showed no effect on restenosis used a 
folate only regiment without pyridoxine/B6/B12. Target vessel revascularization (TVR) was not 
significant in one study, reduced in two, and increased in a study (however, 95% CI of RR crossed 
1). MACE was reduced in two studies and increased in one. A meta-analysis was done the only 
outcome affected was homocysteine level despite high heterogeneity level (MD -3.07 [-3.45 to -
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This study showed that folate regiment can reduce homocysteine level significantly. However, the 
successful reduction in homocysteine through folate regiment translate to neither clinically 
beneficial nor harmful outcome. 
Figure 1. Effect of folate on homocysteine levels 
 
Figure 2. Effect of folate on minimal lumen diameter 
 
Figure 3. Effect of folate on restenosis 
 
Figure 4. Effect of folate on target-vessel revascularization 
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EFFICACY OF PHARMACOLOGICAL THERAPIES FOR MYOCARDIAL 
ISCHEMIA/REPERFUSION INJURY: A SYSTEMATIC REVIEW AND META-
ANALYSIS OF RANDOMIZED CLINICAL TRIALS 
Yusuf Azmi1, Ricardo Adrian Nugraha2 
1Faculty of Medicine Universitas Airlangga, Surabaya – Indonesia 
2Semen Gresik Hospital, Gresik - Indonesia 
 
Objective. Aim of this study is to compare the efficacy of various pharmacological therapies 
(drugs targeting nitric oxide/cyclic guanosine monophosphate signaling pathway; drugs targeting 
mitochondrial function; drugs with indirect or unspecified target) in patients with STEMI 
undergoing PCI. The primary outcome is cardiovascular mortality, and the secondary outcomes 
are left ventricular ejection fraction, recurrent myocardial infarction, hospital readmission for heart 
failure and all-cause mortality. 
 
Methods. We performed a meta-analysis according to PRISMA guideline. Articles were searched 
in following databases: PubMed, EMBASE, Web of Science, and Google Scholar. Using random-
effects meta-regression model, data was pooled to determine relative risk (RR) of primary and 
secondary outcomes. The meta-analysis was conducted using RevMan v.5.3 software. 
 
Result. Total of 28 trials, comprising of 7,173 patients, met our inclusion criteria. Our pooled 
analysis showed that the pharmacological therapies were associated with significant reduction in 
cardiovascular mortality and recurrent MI (RR 0.80, 95%CI 0.65-0.99 and RR 0.62, 95%CI 0.42-
0.90, respectively). Pharmacological therapies were not associated with significant improvement 
of LVEF (MD 0.62, 95%CI: -0.16-1.40), reduction in hospital readmission for HF (RR 0.89, 
95%CI: 0.76-1.06), and all-cause mortality (RR 1.02, 95%CI 0.77-1.36). After subgroup analysis 
according to each drugs’ mechanism of action, only drugs targeting NO/cGMP signaling pathway 
showed consistent results in reducing cardiovascular mortality and recurrent MI (RR 0.75, 95%CI: 
0.57-0.97 and RR 0.56, 95%CI: 0.33-0.96, respectively). Subgroup analysis for drugs with indirect 
or unspecified target also showed significant improvement of LVEF and reduction in hospital 
readmission for HF (MD 1.40, 95%CI: 0.09-2.71 and RR 0.89, 95%CI: 0.28-0.84, respectively). 
 
Conclusion. Administration of drugs targeting NO/cGMP signaling pathway in STEMI patients 
undergoing primary PCI appear to have effect on reducing cardiovascular mortality and recurrent 
MI. The drugs with a broad-spectrum mechanism of action seem to be more effective in increasing 
LVEF and reducing hospital readmission for HF. 
 
Keywords: myocardial infarction; percutaneous coronary intervention; reperfusion injury 
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Fig. 1 Forest Plot for Cardiovascular Mortality 
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Fig.3 Forest Plot for Recurrent Myocardial Infarction (MI) 
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Fig.4 Forest Plot for Hospital Readmission for Heart Failure (HF) 
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MICROVASCULAR OBSTRUCTION AND REPERFUSION STRATEGY IN  
ACUTE ST-ELEVATION MYOCARDIAL INFARCTION:  
A META-ANALYSIS OF MULTICENTER RANDOMIZED CONTROLLED TRIAL 
Ervan Zuhri1,2, Perdana Rezha Kusuma3 
1Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia 
2National Cardiovascular Centre Hospital of Harapan Kita, Jakarta, Indonesia 
3Department of Emergency and Critical Care, Freeport Hospital, Papua, Indonesia 
 
Background. Primary percutaneous coronary intervention (PPCI) is the gold standard in restoring 
reperfusion, but fibrinolysis combined with rescue PCI or routine early PCI strategy, called 
pharmacoinvasive (PhI) strategy, can be considered when optimal door to needle time is not 
feasible. Recent meta-analysis showed that PPCI have better outcomes in reduction of thirty-day 
ischemia incidence and thirty-day re-infarction incidence than PhI strategy. But, in this study, 
microvascular obstruction (MVO) is not assessed. Microvascular obstruction (MVO) is the major 
independent predictors of long-term mortality and heart failure in survivors of STEMI. 
Objective. To assess the effect of PhI strategy and PPCI reperfusion strategy on MVO in patients 
with acute STEMI. 
Method. We systematically searched Pubmed and Cochrane Database-Registry up to September 
2018 for randomized-controlled-trial evaluating the effect of PhI strategy and PPCI reperfusion 
strategy on MVO in patients with acute STEMI. The primary endpoint was MVO. The secondary 
endpoints were incidence of heart failure, left ventricular ejection fraction (LVEF), major bleeding, 
mortality, and re-infarction.  
Result. Eight high quality of multicenter RCT (n=2.352 patients) were included. There is no 
significantly different effect between PhI strategy and PPCI in the incidence of MVO (RR 0.87, 
95% CI 0.62 to 1.24), the incidence of heart failure (RR 0.83, 95% CI 0.56 to 1.23), LVEF (MD -
2.00, 95% CI -7.78 to 3.77), major non-intracranial bleeding (RR 1.20, 95% CI 0.71 to 2.03), 
intracranial bleeding (RR 1.85, 95% CI 0.51 to 6.74), and re-infarction (RR 1.81, 95% CI 0.96 to 
3.40). But, the PhI strategy have higher incidence of mortality than PPCI (RR 1.54, 95% CI 1.01 
to 2.32). 
Conclusion. PhI strategy and PPCI had same outcome in the incidence of MVO and other 
outcomes, except incidence of mortality. PPCI is remain the gold standard in restoring reperfusion 
in STEMI. 
Keywords: Microvascular obstruction, pharmacoinvasive strategy, primary percutaneous 
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Figure 1. Funnel Plot of Included Studies Figure 2. Forrest Plot of Comparison: PhI Strategy vs PPCI, outcome: MVO 
Figure 3. Forrest Plot of Comparison: PhI Strategy vs PPCI, outcome: LVEF Figure 4. Forrest Plot of Comparison: PhI Strategy vs PPCI, outcome: Heart Failure 
Figure 5. Forrest Plot of Comparison: PhI Strategy vs PPCI, outcome: Major Non-
Intracranial Bleeding 
Figure 6. Forrest Plot of Comparison: PhI Strategy vs PPCI, outcome: Intracranial Bleeding 
Figure 7. Forrest Plot of Comparison: PhI Strategy vs PPCI, outcome: Re-infarction Figure 8. Forrest Plot of Comparison: PhI Strategy vs PPCI, outcome: Mortality 
